Everus Stock Up 31% This Past Year -- but One Major Holder Cut Exposure by $1.5 Million

Mountaineer Partners trimmed its Everus Construction Group position by 36,374 shares in Q3, leaving 169,844 shares valued at roughly $14.56 million as of Sept. 30; the fund reported $264.03 million in U.S. equity assets across 36 positions and Everus represented 5.5% of reportable AUM. Everus reported strong fundamentals — Q3 revenue $986.8M (+~30% YoY), EBITDA $89M (+37%), diluted EPS $1.11, backlog $2.95B — and management raised full-year guidance to as much as $3.65B in revenue and $300M in EBITDA, suggesting the fund's sale is portfolio risk-management rather than a verdict on company performance; the stock trades at $87.63, up ~31% over the past year.

Analysis

Market structure: Mountaineer’s small trim in ECG is liquidity-driven profit-taking, not a fundamental verdict — ECG’s backlog ($2.95B) and raised guidance to $3.65B revenue / $300M EBITDA keep demand-side dynamics favorable across data centers, utilities and industrials. Direct winners are specialty contractors, equipment manufacturers, and subcontractors feeding repeat maintenance streams; losers would be commodity-heavy suppliers if capex pivots away from metals. Cross-asset impact is muted: corporate credit spreads could tighten modestly for mid‑cap infrastructure names if capex sustains, while equity volatility in cyclicals (ATI, FCX) may rise on rebalancing flows.

Risk assessment: Tail risks include a sudden regional utility capex pause, a major project cancellation (>5% revenue hit), or a spike in labor/raw-material costs compressing EBITDA by >10% — any of which would materially pressure a 5–12x EBITDA valuation. In the next 2–30 days expect noise from 13F flows and tax‑loss harvesting; over 3–12 months backlog conversion and margin realization are the true tests. Hidden dependencies: ECG’s performance is levered to data‑center build cycles and regional permitting; a slowdown there is second‑order but material. Catalysts to monitor: quarterly backlog conversion rate, new large contract awards, and any utility regulatory changes in the next 90 days.

Trade implications: Tactical long on ECG is attractive given guidance — target 12–18 month hold with defined add-on levels; consider pairing against metal/cyclicals to reduce macro beta. Options: buy 9–15 month LEAP calls for asymmetric upside or, if already long, sell short-dated covered calls to harvest premium while waiting for earnings proofs. Sector rotation: modestly increase allocation to infrastructure/utility services at expense of pure-play metals/materials over the next quarter.

Contrarian angles: The market may under-price ECG’s recurring maintenance revenue and backlog quality — consensus sees Mountaineer’s trim as negative, but concentrated funds trimming often creates temporary selling that can be bought into. Valuation looks reasonable versus guided EBITDA (implied forward EV/EBITDA ~mid‑teens); if multiple funds harvest simultaneously we should expect a 10–20% intraday dislocation, creating tactical entry opportunities. Unintended consequence: aggressive tax/take‑profit selling could mask continued operational outperformance for multiple quarters.

Key Decisions for Investors

• Establish an initial 2% long position in Everus Construction Group (ECG) at market (~$87.6) and plan to scale to 4% if the price retraces to $70–$75 (10–20% dip). Use a hard stop-loss 15% below average cost and target a 12–18 month hold to capture backlog conversion into revenue and EBITDA.
• Buy Jan‑2027 ECG LEAP calls (or nearest long‑dated calls) sized to ~0.5% of portfolio notional to express asymmetric upside; alternatively, if already long, sell 30–60 day covered calls to harvest premium until next quarterly results validate guidance.
• Enter a pair trade: long ECG 2% vs short ATI 1.5% (or short FCX 1% if preferred) to express infrastructure/utility outperformance versus metals cyclicals over a 3–6 month horizon; cut the short if macro PMI >52 or commodity prices rally >15% from current levels.
• Reallocate 1–2% of portfolio from pure metals/mining holdings (FCX, ATI, CENX) into infrastructure/utility service names (ECG and peers) over the next quarter; if ECG backlog conversion falls below 30% annualized or management cuts EBITDA guidance by >10%, revert allocation.